Development
ImmunoPrecise Antibodies Ltd.
IPA
$0.6724
-$0.0296-4.22%
NASDAQ
| 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 8.42% | 5.27% | 0.65% | 2.30% | 4.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.42% | 5.27% | 0.65% | 2.30% | 4.05% |
| Cost of Revenue | 15.30% | 8.85% | 1.89% | -2.17% | 16.62% |
| Gross Profit | 3.02% | 2.48% | -0.31% | 5.96% | -4.06% |
| SG&A Expenses | 2.93% | 9.46% | 14.71% | 16.75% | 15.43% |
| Depreciation & Amortization | 22.10% | 50.15% | 90.90% | 50.03% | 18.62% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.89% | -5.15% | 26.46% | 28.95% | 43.86% |
| Operating Income | 42.09% | 14.23% | -58.35% | -62.19% | -105.54% |
| Income Before Tax | 35.79% | 8.42% | -66.36% | -62.58% | -87.19% |
| Income Tax Expenses | -2,388.35% | -455.77% | -230.85% | -108.88% | -102.25% |
| Earnings from Continuing Operations | 39.10% | 13.88% | -51.05% | -46.49% | -67.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.10% | 13.88% | -51.05% | -46.49% | -67.87% |
| EBIT | 42.09% | 14.23% | -58.35% | -62.19% | -105.54% |
| EBITDA | 45.61% | 18.39% | -66.44% | -75.34% | -133.37% |
| EPS Basic | 44.05% | 25.56% | -19.74% | -17.35% | -38.22% |
| Normalized Basic EPS | 48.04% | 27.03% | -26.64% | -20.76% | -42.54% |
| EPS Diluted | 44.05% | 25.56% | -19.74% | -17.35% | -38.22% |
| Normalized Diluted EPS | 48.04% | 27.03% | -26.64% | -20.76% | -42.54% |
| Average Basic Shares Outstanding | 11.44% | 18.55% | 26.45% | 24.01% | 20.81% |
| Average Diluted Shares Outstanding | 11.44% | 18.55% | 26.45% | 24.01% | 20.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |